Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6621 in metastatic castration-resistant prostate cancer
2025-520626-37-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of selumetinib in prostate cancer (PCa) (4 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events and dose-limiting toxicities, Treatment discontinuation due to toxicity and 2 more. Planned start Jun 2026; status: authorised.
02
Drugs
selumetinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2025-520626-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520626-37-00.